Literature DB >> 12586621

Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome.

Jun Ooi1, Tohru Iseki, Satoshi Takahashi, Akira Tomonari, Koji Ishii, Kashiya Takasugi, Yoko Shimohakamada, Nobuhiro Ohno, Kaoru Uchimaru, Fumitaka Nagamura, Arinobu Tojo, Shigetaka Asano.   

Abstract

We report the results of unrelated cord blood transplantation (CBT) for 13 adult patients with advanced myelodysplastic syndrome (MDS). The median age was 40 years, the median weight was 51 kg, and the median number of infused nucleated cells was 2.43 x 107/kg. Twelve patients had myeloid reconstitution, and the median time to more than 0.5 x 109/L (5 x 108/L) absolute neutrophil count was 22.5 days. A self-sustained platelet count more than 50 x 109/L was achieved in 11 patients at a median time of 49 days. Acute graft versus host disease (GVHD) occurred in 9 of 12 evaluable patients and chronic GVHD in 8 of 11 evaluable patients. Ten patients are alive and free of disease at between 171 and 1558 days after transplantation. The probability of disease-free survival at 2 years was 76.2%. These results suggest that adult advanced MDS patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586621     DOI: 10.1182/blood-2002-12-3917

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Unrelated cord blood transplantation after myeloablative conditioning for adult patients with refractory anemia.

Authors:  Jun Ooi; Tohru Iseki; Satoshi Takahashi; Akira Tomonari; Kashiya Takasugi; Michihiro Uchiyama; Takaaki Konuma; Kenji Fukuno; Yasushi Soda; Nobuhiro Ohno; Fumitaka Nagamura; Kaoru Uchimaru; Arinobu Tojo; Shigetaka Asano
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  Posttransplantation engraftment and safety of cord blood transplantation with grafts containing relatively low cell doses in adults.

Authors:  Satoshi Takahashi; Jun Ooi; Akira Tomonari; Takaaki Konuma; Nobuhiro Tsukada; Arinobu Tojo; Takuhiro Yamaguchi; Shigetaka Asano
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

3.  Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.

Authors:  Takaaki Konuma; Jun Ooi; Hitomi Nagayama; Akira Tomonari; Nobuhiro Tsukada; Seiko Kato; Toshiro Kawakita; Masamichi Isobe; Maki Monna-Oiwa; Arinobu Tojo; Tohru Iseki; Satoshi Takahashi
Journal:  Ann Hematol       Date:  2021-09-30       Impact factor: 3.673

4.  Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival.

Authors:  Priya Kumar; Todd E Defor; Claudio Brunstein; Juliet N Barker; John E Wagner; Daniel J Weisdorf; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2008-12       Impact factor: 5.742

Review 5.  Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?

Authors:  Boglarka Gyurkocza; H Joachim Deeg
Journal:  Blood Rev       Date:  2012-09-13       Impact factor: 8.250

Review 6.  Transplantation for myelodysplastic syndromes 2013.

Authors:  Jennifer E Vaughn; Bart L Scott; H Joachim Deeg
Journal:  Curr Opin Hematol       Date:  2013-11       Impact factor: 3.284

7.  Immune Reactions following Cord Blood Transplantations in Adults.

Authors:  Hiroto Narimatsu
Journal:  Stem Cells Int       Date:  2011-06-05       Impact factor: 5.443

8.  Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation.

Authors:  Ken Ishiyama; Jun Aoki; Hidehiro Itonaga; Naoyuki Uchida; Satoshi Takahashi; Yuju Ohno; Yoshiko Matsuhashi; Toru Sakura; Makoto Onizuka; Shigesaburo Miyakoshi; Minoko Takanashi; Takahiro Fukuda; Yoshiko Atsuta; Shinji Nakao; Yasushi Miyazaki
Journal:  Blood Cancer J       Date:  2019-03-06       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.